ROGER S. MITCHELL, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Iproniazid (the isopropyl derivative of isonicotinic acid hydrazine, "Marsilid"2) was first made available for trial in patients with tuberculosis in June, 1951.1 During the first six months of its use iproniazid was found to be less tuberculostatic than isoniazid in vitro,2 but possibly more effective in relieving tuberculotoxicity than isoniazid in vivo.1, 3 Untoward effects were much more common with iproniazid than with isoniazid.1, 3, 4, 5, 6, 7 While the drug has now been withdrawn from any use in patients because of these side effects, especially of the central nervous system,3, 5, 7, 8 no deaths attributed to iproniazid
MITCHELL RS. FATAL TOXIC ENCEPHALITIS OCCURRING DURING IPRONIAZID THERAPY IN PULMONARY TUBERCULOSIS1. Ann Intern Med. 1955;42:417–424. doi: 10.7326/0003-4819-42-2-417
Download citation file:
Published: Ann Intern Med. 1955;42(2):417-424.
CNS Infections, Infectious Disease, Mycobacterial Infections, Neurology, Pulmonary Tuberculosis.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use